SENTINEL COHORT:
The DEE2012 “KAYAK” study will enroll in two parts: a Sentinel Cohort of 8 participants and a Main Cohort of up to 52 participants. There will be a pause in participants screening and enrollment for data analysis by an independent data monitoring committee (DMC) and any needed protocol amendments following the full enrollment of the Sentinel Cohort. |
To learn more about this study, you or your doctor may contact the study research staff:
Neurocrine Medical Information Call Center 877-641-3461 medinfo@neurocrine.com ClinicalTrials.gov identifier (NCT number): NCT04873869 |
Recruiting
San Francisco, CA
University of California San Francisco UCSF Medical Center San Francisco, California, United States, 94158 Contact: Lucy Liu, 415-353-2437 Lucy.liu3@ucsf.edu Washington, DC Children's National Hospital Washington, District of Columbia, United States, 20010 Contact: Zachary Kramer zkramer@childrensnational.org Chicago, IL Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States, 60611 Contact: Enrique Rojas erojas@luriechildrens.org Rochester, MN Mayo Clinic Rochester, Minnesota, United States, 55905 Contact: Bridget Neja, 507-266-9150 neja.bridget@mayo.edu Rochester, NY University of Rochester Rochester, New York, United States, 14642 Contact: Noreen Connolly Noreen_Connolly@urmc.rochester.edu |
Philadelphia, PA Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Contact: Jennie Minnick ENGIN@chop.edu Fort Worth, TX Cook Children's Medical Center Fort Worth, Texas, United States, 76104 Contact: Dianna Grado, 682-885-2844 Dianna.grado@cookchildrens.org Not Yet Recruiting
Winston-Salem, NC
Wake Forest Baptist Health Winston-Salem, North Carolina, United States, 27157 Contact: Carolyn Hedrick cwhedric@wakehealth.edu Salt Lake City, UT University of Utah Salt Lake City, Utah, United States, 84132 Contact: Carly Straley clinicaltrialsoffice@hsc.utah.edu |
The EMBOLD Study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric patients age 2-18 with DEEs, followed by an open-label extension.
PRAX-562 is a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in early onset SCN2A-DEE and SCN8A-DEE. |
To learn more about this study, you or your doctor may contact the study research staff:
Head of Pharmacovigilance 617-300-8460 clinicaltrials@praxismedicines.com ClinicalTrials.gov identifier (NCT number): NCT05818553 |
Recruiting
Atlanta, GA Praxis Research Site Atlanta, Georgia, United States, 30329 Chicago, IL Praxis Research Site Chicago, Illinois, United States, 60611 Boston, MA Praxis Research Site Boston, Massachusetts, United States, 02115 |
Tacoma, WA Praxis Research Site Tacoma, Washington, United States, 98405 Madrid, Spain Praxis Research Site Madrid, Spain, 28034 Fully remote from your home clinicaltrials@praxismedicines.com |
Kayak Study Update: September 2022
|
Embold Study Update: September 2022
|
Kayak Study Update: April 2023 (update at 5:30 mark)
|
Embold Study Update: April 2023
|
Past Annual Reports
Past PCDH19 Efforts Privacy Policy The Cute Syndrome Foundation PO Box 842 Ozark, MO 65721 |
The Cute Syndrome is registered as a tax-exempt organization under IRS section 501(c)(3).
Our tax identification number is: 46-2699066. © The Cute Syndrome Foundation, All rights reserved |